Skip to main content
Caplight Logo









Code Biotherapeutics

Code Biotherapeutics

Private
Hatfield, PennsylvaniaHealthcare & Life Scienceshttps://www.codebiotx.com/

Last Round

Series A

Jun 7, 2022

Total Funding Raised

$85M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Code Biotherapeutics is a biotechnology company that develops non-viral gene therapies for serious and life-threatening genetic disorders using its proprietary 3DNA delivery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

gene therapynon-viral deliverygenetic medicine3DNAdrug delivery platformrare disease therapybiotech platformsynthetic deliverygene delivery vectorbiotech startupviral vector alternativegenetic payloadnext-gen gene therapyplatform biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Code Biotherapeutics Comparables

Compare Code Biotherapeutics with similar companies based on industry and business-model similarity.

Code Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BreezeBio
87%
Resilience
81%
Mirai Bio
78%

Code Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 7, 2022
SeedApr 20, 2021

Key People

Founding team and executive leadership

John Tattory

Consulting CFO

Executive Team

Code Biotherapeutics Investors

Notable investors and investment history

Code Biotherapeutics investors
InvestorRounds
UCB VenturesSeries A
CureDuchenne VenturesSeed, Series A
New Enterprise Associates (NEA)Series A, Seed
Hatteras Venture PartnersSeries A
4BIO CapitalSeries A, Seed
UCB VenturesSeries A
Northpond VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors grew 45% MoM, reaching 1.4K.

  • Jun 7, 2022

    $75M round led by Northpond Ventures.

Code Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Code Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Code Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHatfield, Pennsylvania
Employee Range23
Year Founded2020
Last FundingJun 7, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?